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A 50-year-old man, in apparently good health, was referred
to the Lipid Center of San Luigi Gonzaga Hospital,
Orbassano (Turin, Italy), by his primary care physician
(PCP) because clinical tests at the time of blood donation
showed milky plasma with serious hypertriglyceridaemia
(>5000 mg/dl) and hyperglycaemia (381 mg/dl), diagnostic
for diabetes. It was not possible to perform further blood
chemical analyses because hypertriglyceridaemia would
have provided abnormal results. The patient entered the hos-
pital to prevent acute pancreatitis, which is often associated
with severe hypertriglyceridaemia.
The clinical history revealed H. pylori-associated gas-
tric ulcer in the prior year. At that time, laboratory tests dis-
closed “mild” hyperglycaemia and hypertriglyceridaemia
(the patient’s records were misplaced.) An ill-defined
hypolipidaemic diet was recommended at discharge, but the
suggestion was neglected. He was a former smoker (30
pack year, stopping about 10 years before), and consumed
a diet rich in saturated fats and carbohydrates while alcohol
ingestion was mild and occasional (2–3 drinks per week).
His living mother was affected by type 2 diabetes; his
father died by accident at a young age, while a brother suf-
fered a myocardial infarction at age 43, seemingly not relat-
ed to traditional cardiovascular risk factors. The patient
weighed 79 kg and was 1.75 m tall (Body Mass Index,
BMI=25.8 kg/m2), and there had been no significant recent
weight modification. No significant abnormalities were
detected at physical examination.
Biochemical analyses (Table 1) corroborated the findings
of severe hypertriglyceridaemia (6.594 mg/dl), showing also
high cholesterol levels (658 mg/dl) and low plasma high-
density lipoprotein cholesterol (HDL-C, 15 mg/dl);
apolipoprotein A-I was 75 mg/dl and apolipoprotein B was
141 mg/dl, both within normal laboratory range. After refrig-
eration overnight at +4°C, serum showed a creamy surface
layer and a turbid infranatant, while lipoprotein elec-
trophoresis disclosed lipids at origin and a broad pre-β band:
both these tests indicated the presence of chylomicrons and
very low-density lipoproteins (VLDLs). Plasma creatinine
was within normal limits, while urinalysis detected trace
amounts of glucose and ketone bodies; liver and thyroid
functions were also normal; γ−glutamyl-transferase was
slightly increased and serum sodium decreased. Glucose
level (215 mg/dl) and glycated haemoglobin (HbA1c) were
increased, C-peptide was in the normal-high range, while
immune parameters were unaffected, in particular anti-
islet cells antibodies (ICA) and glutamic acid decarboxy-
lase antibodies (GADA) were not detected.
Preparative ultracentrifugation was carried out, showing
cholesterol enrichment in the density fraction <1.006 g/ml,
corresponding to chylomicrons+VLDLs. Apolipoprotein E
was homozygous for the most common isoform (ε3/ε3
genotype). We did not disclose a deficiency of apolipopro-
tein C-II, which represents the physiological lipoprotein
lipase (LPL) activator, but we could not directly evaluate
LPL activity.
Supra-aortic and lower limb echo-doppler examination
revealed increased intima-media thickness but no plaques,
while liver echotomography showed diffuse, high-grade
steatosis.
Along with clinical evaluation, dietetic therapy and a
four-injection insulin regimen was administered (3 short-act-
ing pre-prandial insulin, and one bedtime long-acting dose).
Treatment resulted in rapidly improving and rather steady
glycaemic control with progressive reduction of insulin
requirement. At the same time the dyslipidaemia was treated
with low-fat diet, subcutaneous calcium heparin (2000 IU,68
bid), fenofibrate (200 mg, qd) and omega-3 fatty acids (1 g,
tid). Plasma triglycerides decreased in a few days, followed
by blood cholesterol (Fig. 1). After lipid pattern improve-
ment, insulin treatment was completely discontinued, and
the patient was successfully treated with only diet and met-
formin; also subcutaneous heparin was stopped, while
fibrates and polyenoic fatty acids were maintained. His
weight decreased by 3–4 kg during the hospital stay, while 6
months afterwards his BMI was 25.2 kg/m2.
In short, we report a case of a patient with massive dys-
lipidaemia associated with glycaemic decompensation, in
the framework of previously unrecognised type 2 diabetes,
anamnestic hints of “slight”, not further defined, hypergly-
caemia and a familial history of diabetes. Increased HbA1c
plasma levels suggest that diabetic decompensation
occurred during weeks or months before, and not in a few
days time, while high C-peptide plasma levels in the con-
text of overt hyperglycaemia testify to a relative insulin
deficiency and marked insulin resistance. Finally, the
absence of immune markers rule out the presence of latent
autoimmune diabetes in the adult (LADA), a peculiar form
of smoldering type 1 diabetes that appears during adult-
hood. Dyslipidaemia is a common finding in diabetic pop-
ulations, and represents a major coronary heart disease risk
factor [1]. It may be found when type 2 diabetes is diag-
nosed, persisting in spite of hypoglycaemic therapy and
closely related to insulin-resistance parameters. It is gen-
erally characterised by moderate hypertriglyceridaemia
and low HDL-C plasma levels, while total and low-densi-
ty lipoprotein-cholesterol (LDL-C) concentrations are
similar to non-diabetic subjects; however LDL particles
are smaller and denser than usual, and possibly more
atherogenic. Moreover, the LDLs and HDLs are triglyc-
eride-enriched [2, 3]. Less frequently, diabetes begins with
a chylomicronemic syndrome. In our patient, hyperlipi-
daemia was at first characterised by very high triglycerides
and cholesterol plasma levels. Blood triglycerides exceed-
ing 2000 mg/dl are a rare clinical finding; when such val-
ues are present, several haematochemical parameters may
look abnormal as a result of analytical interference or
uneven analyte distribution (the “false” hyponatraemia we
found is ascribable to the presence of sodium only in the
watery plasma phase, while the lipid phase, about 10% of
total plasma volume, is not permeable to sodium).
The most common primary causes of severe hyper-
triglyceridaemia are familial LPL deficiency and familial
apo C-II deficiency (the physiological LPL activator),
which may account for up to 10% of all individuals referred
to a lipid clinic with the chylomicronaemia syndrome [4].
The transient hypertriglyceridaemia of our patient was not
in agreement with familial conditions, characterised by
rather steadily increased lipid values (also above 5–10 000
mg/dl), and not responsive to drug treatment. The coexis-
tence of high plasma cholesterol and triglycerides with
fasting chylomicrons may suggest type III hyperlipidaemia.
This lipid disorder (also known as ‘dysbetalipopro-
teinaemia’ or ‘broad-beta disease’) is a rare condition
(1:10 000 subjects) and much more frequent in subjects
with an uncommon apolipoprotein E genotype (ε2/ε2). It is
characterised by the development of premature atheroscle-
rosis and plasma accumulation of partially catabolised chy-
lomicrons and VLDLs [5]. Dyslipidaemic patients show
increased cholesterol and triglyceride levels (>300 mg/dl)
and a peculiar “broad beta” band between β (LDL) and
pre-β (VLDL) bands at lipoprotein electrophoresis; chy-
lomicrons may be present in variable amounts. In this case,
Table 1 Biochemical tests after hospital admission
Cholesterol 658 mg/dl Anti-insula Ab Negative Uric acid 5.8 mg/dl
Triglycerides 6594 mg/dl Anti-GAD Ab Negative Total proteins 7.8 g/dl
HDL-chol 15 mg/dl Leucocytes 4290/mm3 ALT 26 U/l
Apo AI 75 mg/dl Haemoglobin 14.1 g/dl γ-Glutamyl-transferase 112 U/l
Apo B 141 mg/dl hs-CRP 0.26 mg/dl Bilirubin 0.5 mg/dl
Fasting glycaemia 215 mg/dl Sodium 133 mEq/l Amylase 30 U/L
Glycated haemoglobin 10.5% Potassium 4.5 mEq/l TSH 2.2 µUI/ml
C-peptide 3.5 ng/ml Creatinine 0.9 mg/dl f-Thyroxine 1.2 ng/dl
Fig. 1 Lipoprotein parameters during hospital stay and after dis-
charge69
CE
however, a very distinct electrophoretic β-band and a com-
mon apolipoprotein ε3/ε3 genotype rule out the hypothesis
of type III hyperlipoproteinaemia.
Another rare hyperchylomicronaemic syndrome (with
a prevalence of about 1:10 000 in the general population)
is Fredrickson type V dyslipidaemia. In this condition both
VLDL and chylomicron levels are increased, while plasma
triglycerides are very high. It may display either a primary
or a secondary origin: in the latter case obesity, pregnancy,
ethanol intake, estro-progestins, β-blockers or anion
exchange resins, hypothyroidism, kidney disease and dia-
betes may favour its appearance in predisposed individu-
als. Our patient seems classifiable in this type of dyslipi-
daemia. Likely some concurrent lipid metabolism abnor-
mality (e.g., familial combined hyperlipidaemia or het-
erozygous LPL deficiency) may represent the fuel promot-
ing hyperchylomicronaemia (+VLDLs) in response to
hyperglycaemic decompensation, most probably feed-back
by incoming hypertriglyceridaemia as part of a well known
vicious cycle [6, 7]. This fact might explain both transient
type IIb hyperlipidaemia during clinical type V remission,
and the familial history of coronary heart disease. His lipid
profile 6 months after hospital discharge was alternatively
normal, or suggestive of type IV hyperlipaemia. Our diag-
nosis is probable but the pathophysiology is presumptive,
as important data are lacking (LPL activity or gene
sequencing); however therapy response and patient follow-
up add reliability to this interpretation.
Interestingly our patient was substantially asympto-
matic: clinical complications of hyperchylomicronaemia
(acute pancreatitis, eruptive xanthomatosis) are particularly
common with plasma triglyceride levels above 2000 mg/dl
[4], but sometimes, unpredictably, they may be absent. The
relationship between hyperchylomicronaemia and prema-
ture atherosclerosis is still controversial, denied by most
authors, but has received some valuable confirmation [8].
Treatment improved the lipid pattern after only a few
days. A lipid-poor diet, in particular, represents the corner-
stone of early treatment. Fibrates are then particularly indi-
cated: after interacting with a specific nuclear receptor (per-
oxisome proliferator activated receptor-α,P P A R α), they fas-
ten LPL-induced lipolysis (especially by blocking apo C-III
synthesis, a main lipoprotein lipase-inhibitor), and decrease
liver triglycerides and apolipoprotein B secretion [9]. Heparin
was effective in the short term, but its role in severe hyper-
triglyceridaemia is still under discussion [10]. It has been
defined as a “plasma clearing factor” showing hypotriglyceri-
daemic effect in an acute setting, and may be useful when
pancreatitis supervenes, especially in conjunction with
insulin treatment [10, 11]. Heparin may release LPL from the
endothelial surface of extrahepatic tissues, promoting its
access to blood where the enzyme hydrolyses VLDL and chy-
lomicron triglycerides. However, after a quick peak effect,
chronic heparin infusion causes lipase activity to reach a
plateau that is substantially lower than the former level (about
15%), decreasing correspondingly the tissue stores (likely by
hepatic catabolism of circulating LPL molecules) [12]. This
makes its long-term utilisation particularly questionable.
Omega-3 fatty acids are another debated drug; they display
hypotriglyceridaemic effect when administered to subjects
with high VLDL plasma levels, while in type V patients there
is no consensus on their efficacy (they could even be detri-
mental, favouring chylomicron synthesis in enterocytes).
Also plasmapheresis may represent, in selected contexts, a
useful but extreme therapeutical tool [13].
Finally, insulin effect must not be underestimated: it is
always advisable in diabetic patients when marked hyper-
triglyceridaemia is recognised. In fact insulin can stimu-
late LPL production, inhibit endogenous triglyceride syn-
thesis and promote their catabolism [14].
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Patients with suspected deep vein thrombosis (DVT) or pul-
monary embolism (PE) are frequently admitted to an
Emergency Department (ED) for initial evaluation. However,
management of patients with suspicion of acute venous
thromboembolism (VTE) in this clinical setting can be diffi-
cult; in fact symptoms and signs of DVT are non-specific and
can be found in a broad spectrum of non-thrombotic disor-
ders. An accurate and timely objective diagnosis is necessary
for immediate and correct identification of patients with
acute VTE, while avoiding the bleeding risk associated with
unnecessary anticoagulant therapy in patients where DVT or
PE have been ruled out. The diagnostic approach to patients
with suspected VTE includes clinical evaluation, diagnostic
imaging and D-dimer testing [1, 2].
In a recent issue of Internal and Emergency Medicine,
Siragusa [3] exhaustively discussed the currently used
assays, clinical indications and limitations of D-dimer testing
for managing acute VTE in emergency medicine.
Measurement of D-dimer values, a degradation product of
cross-linked fibrin, is a simple laboratory test, and has been
extensively studied in numerous prospective cohort studies
in cases of suspected DVT or PE, showing a high negative
predictive value. The author [3] shows that D-dimer testing
has sufficient diagnostic accuracy for ruling out acute VTE if
used in combination with standardised clinical judgement.
The review is important for at least three reasons.
First, many physiological and pathological conditions can
increase plasma D-dimer levels (pregnancy, age, trauma, can-
cer, inflammation and several other clinical conditions); on
the other hand D-dimer levels may fail to increase in patients
with acute VTE for multiple reasons (impaired fibrinolytic
activity, use of heparin or oral anticoagulants, onset of symp-
toms more than two weeks before blood sampling). For these
reasons, D-dimer testing has a high sensitivity but a low
specificity in the diagnosis of acute VTE; in clinical practice
it may be associated with frequent “false positive” results, but
also more rarely with “false negative” findings. However, its
use should always be associated with a careful clinical assess-
ment to rule out the presence of acute VTE only in sympto-
matic patients. Overuse or misuse of the D-dimer screen for
VTE may have negative consequences, in terms of a burden
both for patients and for healthcare costs; in fact, despite clin-
ical guidelines, inappropriate and unnecessary measurement
of D-dimer is a significant clinical problem [4].
Second, commercially available assays are very differ-
ent for many reasons. Assays differ in the type of antibody
used as well as in the type of data provided, as some are
qualitative whereas others are quantitative. Moreover, the
value of various D-dimer assays is based upon several fac-
tors including sensitivity, specificity, cost, time required,
reproducibility and complexity. Finally, the diagnostic
accuracy of D-dimer relies on the cut-off values, that is the
range within which the test has the best sensitivity and
specificity, and may be very different comparing one assay
to another. Cut-off points are established by the manufac-
turers, according to the characteristics of D-dimer testing;
a wide range of sensitivities and specificities have been
reported for different D-dimer assays. Currently, no D-
dimer reference standard exists, making interassay corre-
lation poor; moreover, because of variations and differ-
ences among different assays, results from one of them
cannot be extrapolated to another.
Third, another interesting issue concerning the use of
the D-dimer test in emergency medicine is its use when
urgent diagnostic imaging for DVT or PE is not immedi-
ately available, as for example during a night-time or
week-end evaluation. Siragusa and coworkers [5] studied
whether a combined approach consisting of pre-test clini-
cal probability, D-dimer testing and low-molecular-weight
heparin (LMWH) allowed deferral of objective assessment
of DVT or PE for up to 72 h in 409 patients admitted to ED
for suspected VTE. Pending diagnostic confirmation,
patients identified with a high probability or with a mod-
erate probability and positive D-dimer test received a pro-
tective full dose of LMWH, while the remaining patients
were discharged without anticoagulant treatment. The
study demonstrates the safety of this approach.
Despite the promise of these findings, there are sever-
al points of caution worth noting with respect to the use